VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 73.3% in March

VanEck Biotech ETF (NASDAQ:BBH) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 3,100 shares, a decrease of 73.3% from the February 28th total of 11,600 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 10,300 shares, the short-interest ratio is presently 0.3 days.

VanEck Biotech ETF Trading Up 0.5 %

BBH opened at $159.66 on Friday. The firm has a market capitalization of $389.56 million, a PE ratio of 33.67 and a beta of 0.85. VanEck Biotech ETF has a twelve month low of $151.35 and a twelve month high of $183.64. The firm’s 50-day moving average price is $163.02 and its 200 day moving average price is $166.74.

Hedge Funds Weigh In On VanEck Biotech ETF

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in shares of VanEck Biotech ETF by 86.2% in the 4th quarter. Bank of America Corp DE now owns 86,508 shares of the company’s stock worth $13,579,000 after acquiring an additional 40,052 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of VanEck Biotech ETF by 5.7% in the fourth quarter. Wells Fargo & Company MN now owns 75,826 shares of the company’s stock valued at $11,902,000 after purchasing an additional 4,064 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in VanEck Biotech ETF during the fourth quarter worth about $9,966,000. Strategic Financial Concepts LLC purchased a new position in VanEck Biotech ETF during the fourth quarter worth about $3,828,000. Finally, Raymond James Financial Inc. purchased a new position in VanEck Biotech ETF during the fourth quarter worth about $3,381,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.